MX2012002583A - Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. - Google Patents

Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.

Info

Publication number
MX2012002583A
MX2012002583A MX2012002583A MX2012002583A MX2012002583A MX 2012002583 A MX2012002583 A MX 2012002583A MX 2012002583 A MX2012002583 A MX 2012002583A MX 2012002583 A MX2012002583 A MX 2012002583A MX 2012002583 A MX2012002583 A MX 2012002583A
Authority
MX
Mexico
Prior art keywords
positive allosteric
allosteric modulators
receptor positive
aryl methyl
receptor
Prior art date
Application number
MX2012002583A
Other languages
English (en)
Inventor
Scott D Kuduk
Thomas J Greshock
Ronald K Chang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2012002583A publication Critical patent/MX2012002583A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

La presente invención está dirigida a compuestos de piranilo arilo metilo benzoquinazolinona de fórmula (I) (ver fórmula (I)) que son moduladores alostéricos positivos del receptor M1 y que son útiles en el tratamiento de enfermedades en donde esté involucrado el receptor M1, como por ejemplo la enfermedad de Alzheimer, la esquizofrenia, y los trastornos del dolor y del sueño; la invención también está relacionada con composiciones farmacéuticas que comprenden los compuestos, y con el uso de los compuestos y composiciones en el tratamiento de enfermedades mediadas por el receptor M1.
MX2012002583A 2009-08-31 2010-08-26 Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. MX2012002583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23845709P 2009-08-31 2009-08-31
PCT/US2010/046733 WO2011025851A1 (en) 2009-08-31 2010-08-26 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
MX2012002583A true MX2012002583A (es) 2012-04-02

Family

ID=43628378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002583A MX2012002583A (es) 2009-08-31 2010-08-26 Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.

Country Status (27)

Country Link
US (1) US8846702B2 (es)
EP (2) EP2915812A1 (es)
JP (1) JP5658255B2 (es)
KR (1) KR101651312B1 (es)
CN (1) CN102480964B (es)
AU (1) AU2010286683B9 (es)
BR (1) BR112012003464B8 (es)
CA (1) CA2770480C (es)
CO (1) CO6501188A2 (es)
CY (1) CY1116452T1 (es)
DK (1) DK2473048T3 (es)
ES (1) ES2537979T3 (es)
HK (1) HK1208225A1 (es)
HR (1) HRP20150572T1 (es)
HU (1) HUE026296T2 (es)
IL (1) IL217638A (es)
ME (1) ME02151B (es)
MX (1) MX2012002583A (es)
MY (1) MY160075A (es)
NZ (1) NZ598462A (es)
PL (1) PL2473048T3 (es)
PT (1) PT2473048E (es)
RS (1) RS54051B1 (es)
RU (1) RU2507204C2 (es)
SI (1) SI2473048T1 (es)
WO (1) WO2011025851A1 (es)
ZA (1) ZA201201205B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101494059B1 (ko) 2009-12-17 2015-02-16 머크 샤프 앤드 돔 코포레이션 퀴놀린 아미드 ｍ1 수용체 양성 알로스테릭 조절제
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
US8557992B2 (en) 2010-06-15 2013-10-15 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
WO2012158473A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US10323027B2 (en) * 2015-06-26 2019-06-18 Takeda Pharmaceutical Company Limited 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
LT3347349T (lt) * 2015-09-10 2019-12-10 Suven Life Sciences Ltd Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai
EP3366679B1 (en) * 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017151449A1 (en) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulator compounds and methods of use thereof
WO2018194181A1 (en) * 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
CA3113227A1 (en) 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
WO1996038446A1 (fr) * 1995-05-31 1996-12-05 Eisai Co., Ltd. Derives heterocycliques polycycliques fusionnes
EA007483B1 (ru) * 1999-04-30 2006-10-27 Пфайзер Продактс Инк. Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства
WO2001087845A2 (en) * 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
US20060233843A1 (en) 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
WO2008002621A2 (en) * 2006-06-28 2008-01-03 Merck & Co., Inc. Benzyl-substituted quinolone m1 receptor positive allosteric modulators
EP2049503B1 (en) * 2006-07-17 2012-12-19 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
US8492395B2 (en) * 2007-09-26 2013-07-23 Celgene Corporation 7-substituted quinazolinone compounds and compositions comprising the same
NZ592961A (en) * 2008-11-20 2012-09-28 Merck Sharp & Dohme Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
AU2010216263A1 (en) 2009-02-23 2011-07-14 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
WO2011041143A1 (en) 2009-10-01 2011-04-07 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8895580B2 (en) 2009-10-21 2014-11-25 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone M1 receptor positive allosteric modulators
WO2011075371A1 (en) 2009-12-14 2011-06-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
GB0921949D0 (en) 2009-12-16 2010-02-03 Fujifilm Mfg Europe Bv Curable compositions and membranes
WO2011137049A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
HUE026296T2 (en) 2016-06-28
US20120157438A1 (en) 2012-06-21
CN102480964B (zh) 2015-07-08
KR101651312B1 (ko) 2016-08-25
US8846702B2 (en) 2014-09-30
SI2473048T1 (sl) 2015-06-30
CA2770480A1 (en) 2011-03-03
MY160075A (en) 2017-02-15
BR112012003464B1 (pt) 2020-09-01
ES2537979T3 (es) 2015-06-16
EP2915812A1 (en) 2015-09-09
ZA201201205B (en) 2013-04-24
RU2507204C2 (ru) 2014-02-20
RS54051B1 (en) 2015-10-30
EP2473048A1 (en) 2012-07-11
JP2013503177A (ja) 2013-01-31
RU2012112064A (ru) 2013-10-10
AU2010286683B2 (en) 2014-08-07
DK2473048T3 (en) 2015-06-29
BR112012003464A2 (pt) 2015-09-08
WO2011025851A1 (en) 2011-03-03
BR112012003464B8 (pt) 2021-05-25
CN102480964A (zh) 2012-05-30
EP2473048B1 (en) 2015-03-25
ME02151B (me) 2015-10-20
AU2010286683A1 (en) 2012-03-08
CA2770480C (en) 2014-11-18
HK1208225A1 (en) 2016-02-26
IL217638A (en) 2016-08-31
AU2010286683B9 (en) 2014-09-04
CY1116452T1 (el) 2017-03-15
EP2473048A4 (en) 2013-02-13
KR20120073211A (ko) 2012-07-04
PT2473048E (pt) 2015-07-02
HRP20150572T1 (en) 2015-07-03
JP5658255B2 (ja) 2015-01-21
NZ598462A (en) 2012-12-21
CO6501188A2 (es) 2012-08-15
PL2473048T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
GB2511685A (en) Muscarinic m1 receptor agonists
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
ZA201108305B (en) Novel p2x7r antagonists and their use
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX2014014937A (es) Difluoro-hexahidro-ciclopentaoxazinilos y difluoro-hexahidro-benzo oxazinilos como inhibidores de beta-secretasa 1 (bace1).
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
MX342459B (es) 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
JO2919B1 (en) Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FG Grant or registration